Background: The Diabetes Prevention Program (DPP) showed that structured lifestyle interventions can delay or prevent onset of type 2 diabetes in high risk individuals. Despite disproportionate diabetes burdens in low-income individuals, there are no data regarding expected health and economic impacts of structured diabetes prevention in the Medicaid population.

Objective: To examine the net costs and health benefits of extending coverage for structured lifestyle programs to the Medicaid population.

Methods: We modelled a prevention strategy consisting of triannual screening for prediabetes (FPG?100 mg/dl or A1c?5.7%) followed by a DPP-like lifestyle program vs. routine care in non-disabled U.S. Medicaid beneficiaries aged 25-64 years. Medicaid population characteristics were extracted from 2006-2016 NHANES surveys. Costs of diabetes and its complications were estimated from Medicaid administrative claims data of 8 states comprising 52% of the U.S. adult Medicaid population. Based on DPP-like studies in Medicaid populations, we assumed the intervention will reduce diabetes incidence by 32% and will be delivered at costs defined in the Medicare Payment Scheme. We estimated incremental health benefits (in quality-adjusted life-years (QALYs)) gained and net costs (in 2016 U.S. dollars) of screening and delivering lifestyle programs and subtracted savings through prevention of diabetes from a Medicaid perspective over a 10 year time horizon.

Results: Given a 25% screening and intervention uptake in approximately 27 million non-disabled Medicaid beneficiaries across 50 states, extending coverage could prevent or delay 135,000 cases of diabetes, gain 243,000 QALYs, and cost $1.35 billion (incremental cost effectiveness ratio $55,000 per QALY gained).

Conclusions: Extending Medicaid coverage for life-style diabetes prevention programs might be a good use of health care resources and will potentially diminish the diabetes burden in low income individuals.

Disclosure

M. Laxy: None. P. Zhang: None. H. Shao: None. B. Ng: None. M.K. Ali: None. E.W. Gregg: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.